Skip to ContentSkip to Navigation
Rijksuniversiteit Groningenfounded in 1614  -  top 100 university
Over ons Praktische zaken Waar vindt u ons prof. dr. H.J. (Hiddo) Lambers Heerspink

Publicaties

A meta-analysis of albuminuria as a surrogate endpoint for kidney failure

Effects of Dapagliflozin on Health-Related Quality of Life in Patients with CKD

Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysis

Proteins and signalling pathways targeted by dapagliflozin and finerenone: Insights from DAPA-CKD and FIGARO-DKD

Strategies for the development of sodium-glucose cotransporter-2 inhibitors for kidney protection in pediatric chronic kidney disease: proceedings of a workshop meeting in July 2023

Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial

Albuminuria Responses to Dapagliflozin in Patients With Type 2 Diabetes: A Crossover Trial

Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy

A Strategic Roadmap to Support Communication on and Acceptance of Surrogate Endpoints: The REnal Surrogacy accEpTance in Chronic Kidney Disease (RESET CKD) Collaboration

Atrasentan in Patients with IgA Nephropathy.

Pers/media

Finerenone Improves UACR in T1D, CKD

'Nieuw' medicijn vermindert nierschade bij diabetespatiënten

Bayer Aktie: Neue Finanzchefin und Studienerfolg

Kidney drug trial raises hopes for new type 1 diabetes treatment

Hoe afslankmedicijnen het hele lichaam veranderen: ‘Mijn hoofd roept niet meer om eten’

智康弘义宣布SC0062临床II期糖尿病肾病队列研究达到12周主要终点 | 项目进展

Diabetesmedicijn Ozempic heeft ook positief effect bij chronische nierschade

Semaglutide in patinenten met nierziekte